ESC Heart Failure

Papers
(The H4-Index of ESC Heart Failure is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Use of Sodium Glucose Co-Transporter 2 Inhibitors in Acute Heart Failure: A Practical Guidance185
Global Differences in Acute Heart Failure Treatment: Analysis of the STRONG-HF Site Feasibility Questionnaire109
Serum Angiotensin-Converting Enzyme Levels Indicating Early Sarcoidosis Diagnosis and Immunosuppressive Therapy Efficacy89
Establishing a Novel Model to Assess Exercise Capacity in Chronic Heart Failure Based on Stress Echocardiography77
60
Explainable Machine Learning and Online Calculators to Predict Heart Failure Mortality in Intensive Care Units60
58
Editors’ Highlight Picks from 2023 in ESC Heart Failure57
Outcomes with Sacubitril/Valsartan in Outpatients with Heart Failure and Reduced Ejection Fraction: The ARIADNE Registry55
Impact of Age on Characteristics, Performance Measures and Outcomes of Inpatients for Heart Failure in Beijing, China52
New insight: Particle Flow Rate from the Airways as an Indicator of Cardiac Failure in the Intensive Care Unit51
Blood Perfusion Status is Important in the Prognosis of Ventricular Aneurysm Complicated by Ventricular Septal Rupture50
Issue Information49
The Use of MitraClip for Nonobstructive Hypertrophic Cardiomyopathy with Mixed Severe Mitral Valve Regurgitation48
Right Ventricular Strain Predicts Outcome in Patients Receiving Sacubitril/Valsartan: A Sub-Analysis of DISCOVER-ARNI48
Cardiovascular risk associated with polypharmacy in heart failure: a systematic review and meta-analysis48
Prognostic Value of Hypoxaemic Burden from Overnight Oximetry in Heart Failure with Preserved Ejection Fraction47
Glucagon-like peptide-1 receptor agonists for prevention of heart failure events in type 2 diabetes and/or obesity47
Clinical Course of Patients with Hypertrophic Cardiomyopathy Away from Tertiary Referral Care44
The adjusted ferritin inflammation index: a novel metric for predicting mortality in heart failure with reduced and mildly reduced ejection fraction44
Percutaneous Endocardial Alginate–Hydrogel Injection in the Treatment of Heart Failure: First-in-Human Study40
Atrial Fibrillation Ablation in Patients with Arrhythmia-Induced Cardiomyopathy: A Prospective Multicentre Study40
Arterio-venous gradient of active interleukin-18 is associated with diastolic dysfunction: a cross-sectional study39
Predictors of stroke volume improvement with AV-optimized conduction system pacing in patients with AV dromotropathy39
Risk Classification for Long-Term Mortality Among Patients with Acute Heart Failure: China PEACE 4YMortality39
Elevated Activin-A serum levels in patients with acute peripartum cardiomyopathy and during left ventricular recovery37
Calcium Channel Blockers and Clinical Outcomes in Patients with Continuous-Flow Left Ventricular Assist Devices37
Vasopressin in cardiogenic shock: pathophysiology, clinical evidence, and therapeutic perspectives36
Sex Differences in the Impact of Frailty on Patients with Heart Failure: A Retrospective Cohort Study36
Early Achievement of Walkability After Cardiac Surgery and the Risk of Cardiovascular Disease After Hospital Discharge36
Integrated Care for Older Multimorbid Heart Failure Patients: Protocol for the ESCAPE Randomized Trial and Cohort Study36
Biomarker Profiles in Heart Failure with Preserved vs. Reduced Ejection Fraction: Results from the DIAST-CHF Study35
Increased Acylcarnitines in Infant Heart Failure Indicate Fatty Acid Oxidation Inhibition: Towards Therapeutic Options?35
Meta-Analysis Global Group in Chronic Heart Failure Score for the Prediction of Mortality in Valvular Heart Disease35
Heart Failure and Trimethylamine N-Oxide: Time to Transform a ‘Gut Feeling’ in a Fact?35
Closing the gap between trial and clinical reality in long-term left ventricular assist device use outcomes35
0.53852605819702